GeneSight® Psychotropic Test Demonstrated Substantial Cost Savings for Payers in New Study Published in Clinical Therapeutics

Economic Utility Study Showed Annual Cost Savings of $3,988 per Member SALT LAKE CITY, Feb. 23, 2017 (GLOBE NEWSWIRE) -- Assurex Health, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that new data on the use of the GeneSight® Psychotropic test to deliver medication cost savings for mental health disorders was published in [...]

Back to School is Appropriate Time to Evaluate ADHD Medication Choice

Parents often stop children’s ADHD meds at summer break. Now, a genetic test could help ensure they get back on the right ones. MASON, Ohio – August 23, 2016 – During summer months, many parents give their kids a break from the challenges of managing an ADHD medication regimen.  In fact, a review of [...]

Assurex Health to be Acquired by Myriad Genetics

Leader in Precision Medicine for Mental Health Treatment Decisions Sees Significant Strategic Benefits; Will Keep Headquarters in Mason, Ohio MASON, Ohio, August 3, 2016 –  Assurex Health, the world leader in genetic testing to guide behavioral health medication decisions, today announced it will become a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN), [...]

Assurex Health Announces Key Leadership Hires To Support Continued Growth

Eckert, Findley to Guide Legal, People Teams; Verratti to Focus on GeneSight® Adoption Mason, Ohio – March 15, 2016 – Assurex Health, Inc., an informatics-based precision medicine company known primarily for its GeneSight test, a clinically proven test to help enhance medication selection for neuropsychiatric conditions, has announced appointments to three key leadership roles. Inger [...]

Assurex Health Passes Quarter Million Patients Tested with GeneSight

Company Announces Milestone on National Patient Recognition Day   Mason, Ohio – February 3, 2016 – Assurex Health, Inc. marked National Patient Recognition Day today by thanking the 250,000 patients who have taken an important step toward mental wellness through GeneSight® testing and the 15,000 healthcare providers who have used the test to help guide [...]

National Network of Depression Centers and Assurex Health Team up to Tackle Depression

Advertorial, Social Media Campaign to Raise Awareness About the Stigma of Depression and Mental Illness Ann Arbor, MI and Mason, OH – January 28, 2016 – The National Network of Depression Centers (NNDC), along with partner Assurex Health today announced the launch of #tackledepression, a national social media campaign to raise awareness that depression is [...]

Assurex Health Secures $15 Million in New Financing With a Series D Extension

Continues Growth in Industry-Leading Clinical Adoption, Research, and Technology MASON, OH – December 21, 2015 – Assurex Health, Inc., a commercial-stage, informatics-based precision medicine company providing treatment decision support to healthcare providers for behavioral health and chronic pain conditions, has secured an additional $15 million in equity financing from existing Series D investors, according to [...]

Assurex Health Enhances Clinically Proven Genetic Test To Help Healthcare Providers Choose Psychiatric Medications for Patients

GeneSight® Psychotropic Adds 17 New Medications, including medications that treat Anxiety and Bipolar disorder, and Four New Genes to Offer More Comprehensive Test Mason, OH – December 1, 2015 - Assurex Health, Inc. today announced a significant enhancement to its GeneSight® Psychotropic test giving healthcare providers an expanded range of options in helping to make [...]

Assurex Health Tests 200,000 Patients with GeneSight®

Precision Medicine Test Proven to Provide Healthcare Cost Savings, Improve Outcomes MASON, Ohio — (September 23, 2015) – Assurex Health, Inc., a precision medicine company providing treatment decision support to healthcare providers for patients with behavioral health conditions, announced that its GeneSight® test now has been used to help more than 200,000 people on the road [...]

New Study Finds GeneSight (CPGx™) Precision Medicine Test Provides Significant Health Care Cost Savings

Combinatorial approach improves medication adherence and reduces polypharmacy in patients treated with antidepressants and antipsychotics   MASON, Ohio — (August 12, 2015) – A new study published in Current Medical Research and Opinion demonstrated $1,036 in annual prescription savings per patient when healthcare providers used the GeneSight® combinatorial pharmacogenomic (CPGx) test results to guide treatment decisions [...]